Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 29, 2023
Deals
Janssen says half pipeline value will come from outside
What the last two years of BD reveal about the kind of innovation J&J is seeking, and where it’s finding opportunities
BioCentury | Jun 6, 2022
Deals
Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger
Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | Aug 25, 2020
Deals
Reverse merger offers Yumanity faster, less risky path to NASDAQ
Despite continued demand for biotech IPOs, Yumanity has opted to take a less traditional route to the public markets in a move that it views as more efficient and less risky. On Monday, the
BioCentury | Jul 10, 2019
Company News
Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic
BioCentury | Dec 6, 2018
Clinical News
Yumanity reveals Parkinson's candidate as first compound from yeast platform
BioCentury | Dec 4, 2018
Preclinical News
Yumanity reveals Parkinson's candidate as first compound from yeast platform
BioCentury | Nov 3, 2018
Product Development
New partners for NASH
New NASH targets and combinations will be in the spotlight at this year’s AASLD
BioCentury | Feb 16, 2018
Clinical News
Galmed's Aramchol misses in Phase IIa for HIV-associated NAFLD
Items per page:
1 - 10 of 36